Search results

https://academic.oup.com/hmg/article/17/2/170/589691 https://www.nature.com/articles/ncpneuro0679 A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin Enhances autophagy! Which links back to here...

See comment from Jeremy Waletzky on August 4th at the bottom of the comment section. https://www.healthrising.org/blog/2022/07/06/apamycin-resurgence-doctor-chronic-fatigue-syndrome/

So it turns out the person who was highlighted on the Cort Johnson blog as being in remission from rapamune was ALSO taking lithium….. https://www.pnas.org/doi/10.1073/pnas.1913212116 Abstract Increasing life expectancy is causing the prevalence of age-related diseases to rise, and there is an...

I don’t think she defined LC or mentioned MECFS, but may have missed.

Bumping this...starts in 20 minutes...

Merged thread Long Covid webinar, November 2022

Free webinar

Speaking of the devil…

Need clinical trials, so people can get better! 1) cyclophosphamide—Phase 3 is needed with either blinding or a dose response study. 2) Dopamine stabilizer drugs either Aripiprazole (Abilify), Brexpiprazole (Rexulti), cariprazine (Vraylar) or OSU 6162 or all/crossover. Ron Davis estimated...

Zeynep taking on NY Mag article author

OK—advice partially taken—I skimmed it very quickly and saw Adam Gaffney quoted and sort of stopped there. ETA also saw the creepy Canadian guy quoted.

“Komaroff hoped that Abilify’s manufacturer would pick up the tabs for a large Abilify ME/CFS trial.” Nope. Abilify is no longer under patent. However, possible, for Rexulti and Vraylar.

Cort Johnson write-up https://www.healthrising.org/blog/2022/11/03/komaroff-chronic-fatigue-syndrome-long-covid/

@JaimeS Tweeting opposite to what she posted here, in the first post. Still definitely no golden month for me.

Confusingly, the Guardian article mentions both the Astellas and Axcella trials (which are completely different). From the article: “In both ME/CFS and long Covid it’s most likely that these are acquired forms of mitochondrial dysfunction, perhaps related to the initial infection itself or an...

And here’s a Guardian article that mentions the Astellas trial for MECFS and LC. https://www.theguardian.com/science/2022/jun/26/can-our-mitochondria-help-to-beat-long-covid

Correct. Which is why I asked my question about how they developed the inclusion criteria. I’m guessing if they said all MECFS patients could be included, then the trial would fail because at most only 20-25% would respond (the target subset). But I wonder if they could have said 1. an MECFS...

That’s a different clinical trial—Systrom’s is NCT04855201–that one is NCT04641962.